Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2020

Clinical Trials Evaluating IONIS-FB-Lrx

Show Description +

Glenn J. Jaffe, MD, reviews data from a phase 1 study evaluating the safety of an antisense oligonucleotide designed to reduce complement factor B levels in patients with dry AMD in hopes of reducing the spread of disease. Dr. Jaffe provides an overview complement overactivity, introduces viewers to the science of antisense oligonucleotide drugs, and reviews the safety and efficacy of IONIS-FB-Lrx as seen in a phase 1 trial. He also outlines the structure of a phase 2 study evaluating the safety and efficacy of this drug.

Posted: 5/13/2020

Clinical Trials Evaluating IONIS-FB-Lrx

Glenn J. Jaffe, MD, reviews data from a phase 1 study evaluating the safety of an antisense oligonucleotide designed to reduce complement factor B levels in patients with dry AMD in hopes of reducing the spread of disease. Dr. Jaffe provides an overview complement overactivity, introduces viewers to the science of antisense oligonucleotide drugs, and reviews the safety and efficacy of IONIS-FB-Lrx as seen in a phase 1 trial. He also outlines the structure of a phase 2 study evaluating the safety and efficacy of this drug.

Posted: 5/13/2020


Please log in to leave a comment.

More From ARVO: 2020 Coverage

Real-World RVO Treatment Outcomes

Thomas A. Ciulla, MD, MBA

HtrA1 Inhibition for Dry AMD

Dante J. Pieramici, MD

OPTIC Study Data

Arshad M. Khanani, MD